+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030- Product Image
Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030- Product Image
Sale

Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030

  • PDF Icon

    Report

  • 195 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924697
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The CAR T-cell Therapy Market size was estimated at USD 5.08 billion in 2023, USD 5.35 billion in 2024, and is expected to grow at a CAGR of 5.00% to reach USD 7.15 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the CAR T-cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the CAR T-cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the CAR T-cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbClon Inc., Abintus Bio, Inc., AffyImmune Therapeutics Inc., Aleta Biotherapeutics, Amgen Inc., Anixa Biosciences, Inc., Aurora BioPharma, Inc., Autolus Therapeutics PLC, Bellicum Pharmaceuticals, Inc., BioNTech SE, Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd., Cellectis SA, Celyad Oncology SA, Fate Therapeutics, Inc., Gilead Sciences, Inc., Intellia Therapeutics, Inc., Janssen Global Services, LLC by Johnson & Johnson Services, Inc., Legend Biotech Corporation by Genscript Biotech Corporation, Les Laboratories Servier, Mustang Bio by Fortress Biotech, Inc., Noile-immune Biotech, Inc., Novartis AG, Pfizer Inc., and Sorrento Therapeutics, Inc.

Market Segmentation & Coverage

This research report categorizes the CAR T-cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Indication
    • Hematologic Malignancies
      • Leukemia
      • Lymphoma
      • Myeloma
    • Solid Tumors
      • Brain & Central Nervous System
      • Liver Cancer
      • Melanoma
  • End-Use
    • Cancer Treatment Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the CAR T-cell Therapy Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the CAR T-cell Therapy Market?
  3. What are the technology trends and regulatory frameworks in the CAR T-cell Therapy Market?
  4. What is the market share of the leading vendors in the CAR T-cell Therapy Market?
  5. Which modes and strategic moves are suitable for entering the CAR T-cell Therapy Market?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. CAR T-cell Therapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the prevalence of multiple myeloma cancer, lymphoma and leukemia
5.1.1.2. Availability of adequate reimbursements for CAR T-cell therapy with government awareness
5.1.1.3. Increasing adoption of gene and cell therapy
5.1.2. Restraints
5.1.2.1. Limitations of the efficacy of CAR T-cell immunotherapy
5.1.3. Opportunities
5.1.3.1. Exponential R&D funding and partnership for indigenous CAR-T therapy
5.1.3.2. Government support and initiative for the adoption of CAR T-cell immunotherapy
5.1.4. Challenges
5.1.4.1. Concerns associated with safety and possible side effects
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. CAR T-cell Therapy Market, by Indication
6.1. Introduction
6.2. Hematologic Malignancies
6.3.1. Leukemia
6.3.2. Lymphoma
6.3.3. Myeloma
6.3. Solid Tumors
6.4.1. Brain & Central Nervous System
6.4.2. Liver Cancer
6.4.3. Melanoma
7. CAR T-cell Therapy Market, by End-Use
7.1. Introduction
7.2. Cancer Treatment Centers
7.3. Hospitals
8. Americas CAR T-cell Therapy Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific CAR T-cell Therapy Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa CAR T-cell Therapy Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbClon Inc.
12.1.2. Abintus Bio, Inc.
12.1.3. AffyImmune Therapeutics Inc.
12.1.4. Aleta Biotherapeutics
12.1.5. Amgen Inc.
12.1.6. Anixa Biosciences, Inc.
12.1.7. Aurora BioPharma, Inc.
12.1.8. Autolus Therapeutics PLC
12.1.9. Bellicum Pharmaceuticals, Inc.
12.1.10. BioNTech SE
12.1.11. Bristol-Myers Squibb Company
12.1.12. CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd.
12.1.13. Cellectis SA
12.1.14. Celyad Oncology SA
12.1.15. Fate Therapeutics, Inc.
12.1.16. Gilead Sciences, Inc.
12.1.17. Intellia Therapeutics, Inc.
12.1.18. Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
12.1.19. Legend Biotech Corporation by Genscript Biotech Corporation
12.1.20. Les Laboratories Servier
12.1.21. Mustang Bio by Fortress Biotech, Inc.
12.1.22. Noile-immune Biotech, Inc.
12.1.23. Novartis AG
12.1.24. Pfizer Inc.
12.1.25. Sorrento Therapeutics, Inc.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. CAR T-CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. CAR T-CELL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. CAR T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CAR T-CELL THERAPY MARKET DYNAMICS
FIGURE 7. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 8. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 10. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. CAR T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. CAR T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 6. CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 8. CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. CAR T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. CAR T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 13. CAR T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. CAR T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. CAR T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 17. CAR T-CELL THERAPY MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 32. CANADA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. CANADA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 34. CANADA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 35. CANADA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 38. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 39. MEXICO CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CAR T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 54. CHINA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 55. CHINA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 56. CHINA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 57. CHINA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 58. INDIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 59. INDIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 60. INDIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 61. INDIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 66. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 67. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 68. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 69. JAPAN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 70. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 78. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 82. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 86. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 90. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 91. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 92. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 93. THAILAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 94. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 105. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 106. DENMARK CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 107. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 108. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 109. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 110. EGYPT CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 111. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 113. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 114. FINLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 115. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 117. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 118. FRANCE CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 119. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 121. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 127. ITALY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. ITALY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 129. ITALY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 130. ITALY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 131. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 139. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 141. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 142. NORWAY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 143. POLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 144. POLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 145. POLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 146. POLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 147. QATAR CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. QATAR CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 149. QATAR CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 150. QATAR CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 163. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 164. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 165. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 166. SPAIN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 167. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 171. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 175. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 176. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 177. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 178. TURKEY CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM CAR T-CELL THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
TABLE 187. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 188. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 189. CAR T-CELL THERAPY MARKET LICENSE & PRICING

Companies Mentioned

  • AbClon Inc.
  • Abintus Bio, Inc.
  • AffyImmune Therapeutics Inc.
  • Aleta Biotherapeutics
  • Amgen Inc.
  • Anixa Biosciences, Inc.
  • Aurora BioPharma, Inc.
  • Autolus Therapeutics PLC
  • Bellicum Pharmaceuticals, Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics Holdings Limited by Huadong Medicine Co., Ltd.
  • Cellectis SA
  • Celyad Oncology SA
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
  • Legend Biotech Corporation by Genscript Biotech Corporation
  • Les Laboratories Servier
  • Mustang Bio by Fortress Biotech, Inc.
  • Noile-immune Biotech, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sorrento Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.35 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.15 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Global T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Forecast 2024-2030 - Product Image

Global T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Forecast 2024-2030

  • Report
  • 185 Pages
  • Global
From
T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography - Product Image

T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography

  • Report
  • 138 Pages
  • Global
From
T-cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

T-cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Global T-Cell Immunotherapy Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis - Product Image

Global T-Cell Immunotherapy Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • Report
  • 183 Pages
  • Global
From
Global T-Cell Therapy Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global T-Cell Therapy Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 191 Pages
  • Global
From

About the Car T Therapies Market

Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer. Car T therapies are a relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer. Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.